Despite significant setbacks in international aid, global health witnessed notable advancements in 2025, particularly in preventative care strategies. The year saw widespread adoption of a single-dose human papillomavirus (HPV) vaccine regimen, offering a more accessible and cost-effective method of cervical cancer prevention in countries like Pakistan.

The shift to a single-dose strategy followed years of research demonstrating its efficacy, especially for younger girls. Older girls can benefit from two doses. This development is particularly significant in low- and middle-income countries where multi-dose vaccine schedules can be challenging to implement due to logistical and economic constraints.

However, these advancements occurred against a backdrop of considerable challenges. The dissolution of the United States Agency for International Development (USAID) and subsequent budget cuts by the U.S. government significantly impacted global health programs. These cuts affected disease control initiatives, free healthcare provisions, and maternal and child health services.

The U.S. was not alone in reducing its commitment to global health. France, Germany, and the United Kingdom also re-evaluated their priorities, leading to decreased funding for international health initiatives. This collective reduction in financial support created a turbulent environment for organizations working to improve health outcomes worldwide.

Despite these financial constraints, the adoption of the single-dose HPV vaccine represents a positive step forward. The hope is that this streamlined approach will enable wider coverage and contribute to the long-term reduction of cervical cancer incidence globally. The World Health Organization is expected to release updated guidelines reflecting the growing evidence supporting the single-dose regimen, potentially influencing vaccine strategies in additional countries in the coming years.